Fig. 3

Survivals of patients with IPF with or without switching antifibrotics: Switched cases versus Non-switched cases. Survival of patients with IPF with or without antifibrotic switching (A). Survival of propensity-matched patients with or without antifibrotic switching (B). p values were determined by the log-rank test. Cumulative survival probabilities from initiation of antifibrotic therapy were calculated. An event was defined as death from any cause and patients who were lost or still alive were censored at the last follow-up date